MBX Biosciences, Inc. Common Stock

Day range

$52.94 – $57.11

Open

$54.49

Prev close

$54.51

Volume

855.45K

Market cap

$2.71B

Shares out

48.16M

• Investor presentationNov 9, 2026

  On November 9, 2026, the Company updated its corporate presentation. The corporate presentation is available in the "Investors" section of the Company's website at www.mbxbio.com and is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

• Equity compensation grantOct 22, 2026

  In connection with his appointment as a non-employee director, Mr. Radovich will receive compensation, including an initial award of a non-qualified stock option to purchase 18,200 shares of the Company's common stock, to be granted on the appointment date of October 20, 2026.

• Investor presentationAug 6, 2026

  On August 6, 2026, the Company updated its corporate presentation. The corporate presentation is available in the "Investors" section of the Company's website at www.mbxbio.com and is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

• Equity compensation grantJul 13, 2026

  In addition, Mr. Hoerter will be granted equity awards on August 3, 2026. The equity awards will consist of (i) nonqualified stock options to purchase 331,000 shares of the Company's Common Stock, and (ii) a restricted stock unit award covering 71,000 shares of the Company's Common Stock under the 2024 Plan.

• Investor presentationJun 12, 2026

  On June 12, 2026 at 8:00 a.m. E.T., the Company will host a conference call and webcast to discuss the one-year data from the Phase 2 Avail™ and open-label extension clinical trials. A copy of the presentation from the event will be available in the 'Investors' section of the Company's website at www.mbxbio.com and is furnished as Exhibit 99.2.

Days to cover

7.9

Short interest

4.29M

Avg volume

542.47K

As of Oct 30, 2026 · reported to FINRA twice monthly.

• MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
  positiveGlobeNewswire Inc.· Jun 12, 2026
• AstraZeneca's Rare Disease Drug Shows Reduced Dependence On Calcium Supplements
  positiveBenzinga· May 12, 2026
• MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
  positiveGlobeNewswire Inc.· May 11, 2026
• MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  positiveGlobeNewswire Inc.· Apr 3, 2026
• This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones
  neutralThe Motley Fool· Dec 3, 2025